A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma–LuDO-N

Fredrik Sundquist; Kleopatra Georgantzi; Kirsten Brunsvig Jarvis; Jesper Brok; M. Koskenvuo; Jelena Rascon; Max M. van Noesel; Per Grybäck; Joachim N. Nilsson; Arthur J. A. T. Braat; Mikael Sundin; Sandra Wessman; Nikolas Herold; Lars Hjorth; Per Kogner; Donald Granberg; Mark N. Gaze; Jakob Stenman

doi:10.3389/fped.2022.836230

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

In this paper we present the protocol of the LuDO-N Trial. The rationale and design of the trial are discussed in relation to other ongoing, or planned trials with similar objectives. Further, we discuss the rapid development of targeted radiopharmaceutical therapy and the future perspectives for developing novel therapies for high-risk neuroblastoma and other pediatric solid tumors.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sundquist et al. (2022) studied this question.

synapsesocial.com/papers/69d77b963fae90fd6048f4d0 https://doi.org/10.3389/fped.2022.836230

View Full Paper

Ask AI

Bookmark

Share

A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma–LuDO-N

Ask about this paper

Abstract

Discussion

Cite This Study

A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma–LuDO-N

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading